In ovarian cancer cells, berberine could reduce the expression of both EGFR and HER2 and suppress their targets, cyclin D1, matrix metalloproteinases and vascular endothelial growth factor (VEGF). The gene discussed is ERBB2; the disease is ovarian carcinoma.